Oragenics Inc (OGEN) FinancialsOGENOragenics Inc

Evaluating the bottom line, Oragenics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1307.06%, provide a clear picture of how effectively OGEN converts its operational activities into shareholder value.

In the context of the broader market, OGEN competes directly with industry leaders such as KAPA and XRTX. With a market capitalization of $1.55M, it holds a significant position in the sector. When comparing efficiency, OGEN's gross margin of N/A stands against KAPA's N/A and XRTX's N/A. Such benchmarking helps identify whether Oragenics Inc is trading at a premium or discount relative to its financial performance.

Oragenics has reported continuous net income losses, with the latest quarter showing a loss of 2.2 million USD. The company's gross profit is also negative, indicating financial struggles. The current ratio is 3.01, suggesting liquidity but not enough to offset the ongoing losses.